01—Abstract
Summary
Summary of the 8-K filed March 31, 2026. Cited figures are marked; the original filing is the authoritative source.
On March 31, 2026, Biogen (BIIB) agreed to acquire Apellis Pharmaceuticals (APLS) through a two-step transaction: a cash tender offer at $41.00a per share, followed by a second-step merger under DGCL Section 251(h) with no stockholder vote required.
The upfront equity value is approximately $5.6 billionb. Each Apellis share also receives one non-transferable contingent value right (CVR) worth up to $4.00 in cash, tied to annual global net sales of SYFOVRE®: $2.00 if sales reach $1.5 billion in any year from 2027 to 2030, a further $2.00 if sales reach $2.0 billion in any year from 2027 to 2030, or $4.00 if the $2.0 billion threshold is first met in 2031 (and the $1.5 billion milestone was not previously met by December 31, 2030). Each milestone pays only once.
The deal is financed with roughly $3.6 billionc of cash on hand and about $2 billion of revolving credit and bank loans, and Biogen expects to de-lever by year-end 2027. The strategic rationale centers on Apellis's two marketed complement-inhibitor products, EMPAVELI® and SYFOVRE®, which generated combined 2025 net product revenue of $689 million and are expected to grow in the mid-to-high teens at least through 2028. The acquisition also gives Biogen U.S. nephrology commercial infrastructure ahead of a potential felzartamab launch, with the first Phase 3 readout expected in the first half of 2027.
Management expects the deal to be increasingly accretive to non-GAAP diluted EPS starting in 2027 and to meaningfully raise Biogen's non-GAAP EPS CAGR through the end of the decade. Biogen plans to update full-year 2026 guidance with its Q1 2026 earnings. Closing is expected in the second quarter of 2026, subject to the tender offer minimum condition (a majority of outstanding shares), HSR clearance, and other customary conditions.
The agreement includes a $205 milliond termination fee payable by Apellis in specified circumstances, including a superior proposal or a withdrawal of board recommendation. The outside date for the tender offer is September 30, 2026.
Support stockholders holding about 14% of Apellis shares, including Morningside Venture Investments and several Apellis directors and officers, have agreed to tender and vote in favor, which provides meaningful deal certainty. The filing does not disclose the offer's commencement date, which is still pending.
02—Key points
Key Highlights
- Biogen will acquire Apellis for $41.00 per share in cash, an upfront equity value of approximately $5.6 billion, plus one non-transferable CVR per share
- CVR payments of up to $4.00 per share are tied to annual global SYFOVRE® net sales: $2.00 at $1.5B and $2.00 at $2.0B (2027–2030), or $4.00 if $2.0B is first reached in 2031
- Apellis's EMPAVELI® and SYFOVRE® generated $689M in combined 2025 net product revenue, expected to grow mid-to-high teens at least through 2028
- Transaction financed with ~$3.6B cash on hand and ~$2B in revolver and bank loans; Biogen expects to de-lever by year-end 2027
- Biogen expects the deal to be increasingly accretive to non-GAAP diluted EPS starting in 2027 and to meaningfully increase its non-GAAP EPS CAGR through 2030
- Support stockholders representing ~14% of Apellis shares have agreed to tender and vote in favor; the Apellis board unanimously recommends the offer
- Apellis owes a $205M termination fee in specified circumstances; the tender offer outside date is September 30, 2026, and closing is expected in Q2 2026
03—Questions
Frequently Asked Questions
What is the total value of the Apellis acquisition for Biogen shareholders?
The upfront cash consideration is $41.00 per Apellis share, or approximately $5.6 billion in equity value. Each share also carries a CVR worth up to $4.00 in cash, so total potential consideration could reach roughly $5.6 billion plus CVR payments of up to about $4.00 per share, depending on whether SYFOVRE® sales milestones are met.
What must happen for the CVR payments to be made?
Payments depend on annual global net sales of SYFOVRE®. Holders receive $2.00 per CVR if sales reach $1.5 billion in any calendar year from 2027 to 2030, and another $2.00 if sales reach $2.0 billion in any of those years. If neither is met by 2030 but sales reach $2.0 billion in 2031, the payment is $4.00. Each milestone pays only once, and there is no assurance any milestone will be achieved.
How will Biogen pay for the acquisition, and what is the impact on its balance sheet?
Biogen plans to use approximately $3.6 billion of cash on hand and about $2 billion from a revolving credit facility and bank loan. Management believes it can fully de-lever by the end of 2027 while retaining financial flexibility for other investments.
What are the main risks that could prevent the deal from closing?
Key risks include failure to meet the minimum tender condition (a majority of outstanding Apellis shares, not waivable by Biogen without Apellis consent), failure to obtain HSR or other required regulatory approvals, and the possibility of a competing superior proposal. Apellis would owe Biogen a $205 million termination fee in certain circumstances, and the outside date is September 30, 2026.
When is the deal expected to close and how will it affect Biogen's earnings?
Closing is expected in the second quarter of 2026. Biogen expects the transaction to be increasingly accretive to non-GAAP diluted EPS starting in 2027 and to meaningfully raise its non-GAAP EPS CAGR through the end of the decade. Biogen plans to update full-year 2026 guidance with its Q1 2026 earnings report.
04—Continue